Cardiovascular and renal surrogate markers in the clinical management of hypertension

Cardiovascular Drugs and Therapy

Volumn 23, Issue 4, 2009, Pages 317-326

  Maisel, Alan S ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Aliskiren; Heart failure; Hypertension; Kidney impairments; Left ventricle enlargement; Surrogate markers

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HORMONE PRECURSOR; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LIPOCALIN; LISINOPRIL; LOSARTAN; NIFEDIPINE; PERINDOPRIL; VALSARTAN;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE MARKER; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MICROALBUMINURIA; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; URINARY EXCRETION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; KIDNEY DISEASES; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM;

EID: 69249211004     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6177-4     Document Type: Article

References (75)

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95. doi: 10.1067/mcp.2001.113989. (Pubitemid 32225406)
2. M Desai N Stockbridge R Temple 2006 Blood pressure as an example of a biomarker that functions as a surrogate AAPS J 8 E146 52 10.1208/aapsj080117
3. R Temple 1999 Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282 790 5 10.1001/jama.282.8.790 (Pubitemid 29404390)
4. TR Fleming RL Prentice MS Pepe D Glidden 1994 Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research Stat Med 13 955 68 10.1002/sim.4780130906
5. RL Prentice 1989 Surrogate endpoints in clinical trials: definition and operational criteria Stat Med 8 431 40 10.1002/sim.4780080407
6. TR Fleming DL DeMets 1996 Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 605 13
7. DA Morrow JA de Lemos 2007 Benchmarks for the assessment of novel cardiovascular biomarkers Circulation 115 949 52 10.1161/CIRCULATIONAHA.106. 683110 (Pubitemid 46328287)
8. AV Chobanian GL Bakris HR Black, et al. 2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 1206 52 10.1161/01.HYP.0000107251.49515.c2 (Pubitemid 37553153)
9. DA Calhoun D Jones S Textor, et al. 2008 Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation 117 e510 26 10.1161/CIRCULATIONAHA.108.189141
10. P Knaapen T Germans PG Camici, et al. 2008 Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy Am J Physiol Heart Circ Physiol 294 H986 93 10.1152/ajpheart.00233.2007 (Pubitemid 351253312)
11. MJ Koren RB Devereux PN Casale DD Savage JH Laragh 1991 Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension Ann Intern Med 114 345 52
12. JD Tune 2007 Control of coronary blood flow during hypoxemia Adv Exp Med Biol 618 25 39 10.1007/978-0-387-75434-5-3
13. S Lewington R Clarke N Qizilbash R Peto R Collins 2002 Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903 13 10.1016/S0140-6736(02) 11911-8
14. R Collins R Peto J Godwin S MacMahon 1990 Blood pressure and coronary heart disease Lancet 336 370 1 10.1016/0140-6736(90) 91908-S
15. R Collins R Peto S MacMahon, et al. 1990 Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context Lancet 335 827 38 10.1016/0140-6736(90)90944-Z (Pubitemid 20113741)
16. S MacMahon R Peto J Cutler, et al. 1990 Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias Lancet 335 765 74 10.1016/0140-6736(90)90878-9 (Pubitemid 20106689)
17. QL Zhang D Rothenbacher 2008 Prevalence of chronic kidney disease in population-based studies: systematic review BMC Public Health 8 117 10.1186/1471-2458-8-117 (Pubitemid 351678123)
18. CY Hsu CE McCulloch C Iribarren J Darbinian AS Go 2006 Body mass index and risk for end-stage renal disease Ann Intern Med 144 21 8
19. PA McCullough S Li CT Jurkovitz, et al. 2008 CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004 Am J Kidney Dis 51 S38 45 10.1053/j.ajkd.2007.12.017
20. YM Barri 2008 Hypertension and kidney disease: a deadly connection Curr Hypertens Rep 10 39 45 10.1007/s11906-008-0009-y (Pubitemid 351255952)
21. GL Bakris M Williams L Dworkin, et al. 2000 Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Am J Kidney Dis 36 646 61
22. B Zethelius L Berglund J Sundstrom, et al. 2008 Use of multiple biomarkers to improve the prediction of death from cardiovascular causes N Engl J Med 358 2107 16 10.1056/NEJMoa0707064 (Pubitemid 351679597)
23. SA Atlas 2007 The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition J Manag Care Pharm 13 9 20
24. RW Piepho J Beal 2000 An overview of antihypertensive therapy in the 20th century J Clin Pharmacol 40 967 77 10.1177/00912700022009693
25. V Bhatia P Nayyar S Dhindsa 2003 Brain natriuretic peptide in diagnosis and treatment of heart failure J Postgrad Med 49 182 5
26. M Weber C Hamm 2006 Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine Heart 92 843 9 10.1136/hrt.2005.071233 (Pubitemid 43799232)
27. ER Levin DG Gardner WK Samson 1998 Natriuretic peptides N Engl J Med 339 321 8 10.1056/NEJM199807303390507 (Pubitemid 28366422)
28. PA McCullough RM Nowak J McCord, et al. 2002 B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study Circulation 106 416 22 10.1161/01.CIR.0000025242.79963.4C (Pubitemid 34803684)
29. JL Januzzi Jr CA Camargo S Anwaruddin, et al. 2005 The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study Am J Cardiol 95 948 54 10.1016/j.amjcard.2004.12.032 (Pubitemid 40487743)
30. R Latini S Masson M Wong, et al. 2006 Incremental prognostic value of changes in B-type natriuretic peptide in heart failure Am J Med 119 e23 30
31. CM Balion P Santaguida R McKelvie, et al. 2008 Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP Clin Biochem 41 231 9 10.1016/j.clinbiochem.2007.10.005 (Pubitemid 351240899)
32. J Hogenhuis AA Voors T Jaarsma, et al. 2007 Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure Eur J Heart Fail 9 787 94 10.1016/j.ejheart.2007.04.001 (Pubitemid 47212827)
33. A Luchner C Hengstenberg H Lowel, et al. 2005 Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP Hypertension 46 118 23 10.1161/01.HYP.0000170140.36633.8f (Pubitemid 40946501)
34. M Suzuki M Hamada K Yamamoto Y Kazatani K Hiwada 2002 Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events Hypertens Res 25 669 76 10.1291/hypres.25.669
35. MH Olsen TW Hansen MK Christensen, et al. 2005 N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome Hypertension 46 660 6 10.1161/01.HYP. 0000179575.13739.72 (Pubitemid 43186736)
36. P Hildebrandt M Boesen M Olsen K Wachtell B Groenning 2004 N-terminal pro brain natriuretic peptide in arterial hypertension-a marker for left ventricular dimensions and prognosis Eur J Heart Fail 6 313 7 10.1016/j.ejheart.2004.01.001 (Pubitemid 38253051)
37. B Dahlof RB Devereux SE Kjeldsen, et al. 2002 Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 995 1003 10.1016/S0140-6736(02)08089-3 (Pubitemid 34286536)
38. MH Olsen K Wachtell OW Nielsen, et al. 2006 N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy J Hypertens 24 1531 9 10.1097/01.hjh.0000239288.10013.04 (Pubitemid 44162454)
39. JN Cohn G Tognoni 2001 A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 1667 75 10.1056/NEJMoa010713 (Pubitemid 33126822)
40. D Westermann R Schmieder HP Schultheiss C Tschope 2008 Renin inhibitors, clinical experience J Mol Med 86 691 5 10.1007/s00109-008-0338-y
41. JJV McMurray B Pitt R Latini, et al. 2008 Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure Circ Heart Fail 1 17 24
42. A Recio-Mayoral JC Kaski JJ McMurray, et al. 2007 Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY Cardiovasc Drugs Ther 21 459 65 10.1007/s10557-007-6069-4 (Pubitemid 50002142)
43. RB Devereux 2000 Therapeutic options in minimizing left ventricular hypertrophy Am Heart J 139 S9 14 10.1067/mhj.2000.102902
44. G Schillaci P Verdecchia C Porcellati, et al. 2000 Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension Hypertension 35 580 6
45. IW Hammond RB Devereux MH Alderman, et al. 1986 The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension J Am Coll Cardiol 7 639 50
46. PR Liebson G Grandits R Prineas, et al. 1993 Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS) Circulation 87 476 86
47. PM Okin RB Devereux S Jern, et al. 2003 Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study Circulation 108 684 90 10.1161/01.CIR.0000083724.28630.C3 (Pubitemid 36999252)
48. P Verdecchia G Schillaci C Borgioni, et al. 1998 Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension J Am Coll Cardiol 31 383 90 10.1016/S0735-1097(97)00493- 2 (Pubitemid 28153459)
49. E Casiglia L Schiavon V Tikhonoff, et al. 2008 Electrocardiographic criteria of left ventricular hypertrophy in general population Eur J Epidemiol 23 261 71 10.1007/s10654-008-9234-6
50. JM Gardin R McClelland D Kitzman, et al. 2001 M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study) Am J Cardiol 87 1051 7 10.1016/S0002-9149(01)01460-6 (Pubitemid 32710318)
51. D Levy 1991 Clinical significance of left ventricular hypertrophy: insights from the Framingham Study J Cardiovasc Pharmacol 17 S1 6 10.1097/00005344-199117002-00002
52. D Levy M Salomon RB D'Agostino AJ Belanger WB Kannel 1994 Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy Circulation 90 1786 93
53. G de Simone JS Gottdiener M Chinali MS Maurer 2008 Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study Eur Heart J 29 741 7 10.1093/eurheartj/ehm605
54. M Rosenberg C Zugck M Nelles, et al. 2008 Osteopontin, a new prognostic biomarker in patients with chronic heart failure Circ Heart Fail 1 43 9
55. DS Lee RS Vasan 2005 Novel markers for heart failure diagnosis and prognosis Curr Opin Cardiol 20 201 10 10.1097/01.hco.0000161832.04952.6a (Pubitemid 40704877)
56. LM Ruilope RE Schmieder 2008 Left ventricular hypertrophy and clinical outcomes in hypertensive patients Am J Hypertens 21 500 8 10.1038/ajh.2008.16 (Pubitemid 351589672)
57. P Gosse DJ Sheridan F Zannad, et al. 2000 Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study J Hypertens 18 1465 75 10.1097/00004872- 200018100-00015
58. RB Devereux V Palmieri N Sharpe, et al. 2001 Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial Circulation 104 1248 54 10.1161/hc3601.095927
59. B Pitt N Reichek R Willenbrock, et al. 2003 Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study Circulation 108 1831 8 10.1161/01.CIR.0000091405.00772.6E (Pubitemid 37296092)
60. B Dahlof P Gosse P Gueret, et al. 2005 Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study J Hypertens 23 2063 70
61. Solomon S, Appelbaum E, Manning W, et al. Effect of the direct renin inhibitor aliskiren either alone or in combination with losartan, compared to losartan, on left ventricular mass in patients with hypertension and left ventricular hypertrophy (ALLAY) trial [late breaker presentation]. Presented at: American College of Cardiology Scientific Sessions; March 29-April 1, 2008; Chicago, IL.
62. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
63. WY So AP Kong RC Ma, et al. 2006 Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients Diabetes Care 29 2046 52 10.2337/dc06-0248 (Pubitemid 44871185)
64. M Cirillo MP Lanti A Menotti, et al. 2008 Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate Arch Intern Med 168 617 24 10.1001/archinte.168.6.617
65. SM Marshall 1991 Screening for microalbuminuria: which measurement? Diabet Med 8 706 11
66. JS Jensen P Clausen K Borch-Johnsen G Jensen B Feldt-Rasmussen 1997 Detecting microalbuminuria by urinary albumin/creatinine concentration ratio Nephrol Dial Transplant 12 6 9 10.1093/ndt/12.1.6
67. F Chiarelli A Verrotti A Mohn G Morgese 1997 The importance of microalbuminuria as an indicator of incipient diabetic nephropathy: therapeutic implications Ann Med 29 439 45 10.3109/07853899708999374
68. D de Zeeuw 2004 Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 66 S2 6 10.1111/j.1523-1755. 2004.09201.x
69. H Ibsen MH Olsen K Wachtell, et al. 2005 Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study Hypertension 45 198 202 10.1161/01.HYP.0000154082.72286.2a (Pubitemid 40179960)
70. A Servais P Giral M Bernard, et al. 2008 Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med 121 426 32 10.1016/j.amjmed.2008.01.040 (Pubitemid 351626012)
71. J Malyszko H Bachorzewska-Gajewska JS Malyszko K Pawlak S Dobrzycki 2008 Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease Nephrol Carlton 13 153 6 10.1111/j.1440-1797.2007.00899.x (Pubitemid 351232835)
72. CE Mogensen S Neldam I Tikkanen, et al. 2000 Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ 321 1440 4 10.1136/bmj.321.7274. 1440
73. BM Brenner ME Cooper D de Zeeuw, et al. 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 9 10.1056/NEJMoa011161 (Pubitemid 34940825)
74. RC Atkins EM Briganti JB Lewis, et al. 2005 Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy Am J Kidney Dis 45 281 7 10.1053/j.ajkd.2004.10.019 (Pubitemid 40431053)
75. HH Parving F Persson JB Lewis EJ Lewis NK Hollenberg 2008 Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2433 46 10.1056/NEJMoa0708379 (Pubitemid 351793017)